<DOC>
	<DOCNO>NCT02544451</DOCNO>
	<brief_summary>Study 110 Phase 3 , multicenter study subject age 6 year older cystic fibrosis ( CF ) homozygous F508del-CF transmembrane conductance regulator ( CFTR ) mutation participate Study 109 ( NCT02514473 ) Study 011B ( NCT01897233 ) . Study 110 design evaluate safety efficacy long term treatment lumacaftor combination ivacaftor .</brief_summary>
	<brief_title>Rollover Study Evaluate Safety Efficacy Long-term Treatment With Lumacaftor Combination With Ivacaftor</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Subjects enter Treatment Cohort must meet following criterion : Completed study visit Week 24 Study 109 Week 26 Study 011B permanently discontinue treatment Willing remain stable CF medication Safety Followup Visit . Subjects enter Observational Cohort must meet 1 follow criterion : Completed 24 week study drug treatment Study 109 complete 24 week study drug treatment Week 26 Safety Follow Study 011B . Received least 4 week study drug complete visit Week 24 Study 109 Week 26 Study 011B . Exclusion Criteria ( Treatment Cohort Only ) : History comorbidity laboratory abnormality , opinion investigator , might confound result study pose additional risk administer study drug subject ( e.g. , cirrhosis portal hypertension ) . Pregnant nursing female . Sexually active subject reproductive potential willing follow contraception requirement . History drug intolerance prior study would pose additional risk subject opinion investigator History poor compliance study drug and/or procedure previous study deem investigator . Participation investigational drug trial ( include study investigate lumacaftor and/or ivacaftor ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>